Margaret Parker, MD, MCCM, speaks with Joshua N. Goldstein, MD, PhD, FACEP, FAHA, about the article, “Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial,” published in The Lancet. Dr. Goldstein works as an Associate Professor of Surgery at Harvard Medical School. He also serves as Director of the Center for Neurologic Emergencies at Massachusetts General Hospital in Boston, Massachusetts. In this article, Dr. Goldstein and coauthors compared the efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) with that of plasma in VKA-treated patients needing urgent surgical or invasive procedures.
